Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C

CompletedOBSERVATIONAL
Enrollment

256

Participants

Timeline

Start Date

July 7, 2016

Primary Completion Date

October 21, 2018

Study Completion Date

October 21, 2018

Conditions
Chronic Hepatitis C
Interventions
DRUG

Ombitasvir/paritaprevir/ritonavir

Co-formulated tablet

DRUG

Dasabuvir

Tablet

DRUG

Ribavirin

Tablet

BEHAVIORAL

Patient support program

Supportive services provided to participants included reminder calls, emails, text messages, a Care Coach, and educational/informational materials.

Trial Locations (18)

18341

Ha'Emek Medical Center /ID# 153695, Afula

22100

Western Galilee Medical Center /ID# 153705, Nahariya

38100

Hillel Yaffe Medical Center /ID# 153702, Hadera

44281

Meir Medical Center /ID# 153698, Kfar Saba

58100

The Edith Wolfson Medical Cent /ID# 153706, Holon

70300

Assaf Harofeh Medical Center /ID# 153708, Be’er Ya‘aqov

84101

Soroka Medical Center /ID# 169357, Beersheba

Soroka Medical Ctr /ID# 153697, Beersheba

91031

Shaare Zedek Medical Center /ID# 153699, Jerusalem

91120

Hadassah /ID# 153701, Jerusalem

3109601

Rambam Health Care Campus /ID# 153694, Haifa

3339419

Bnai Zion Medical Center /ID# 153700, Haifa

3436212

The Lady Davis Carmel MC /ID# 153692, Haifa

4941492

Rabin Medical Center /ID# 153696, Petakh Tikva

Rabin Medical Center /ID# 158648, Petakh Tikva

5262100

Sheba Medical Center /ID# 153707, Ramat Gan

6423906

Tel Aviv Sourasky Medical Ctr /ID# 153693, Tel Aviv

7565016

Maccabi Health Services /ID# 158647, GUSH DAN

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY